ADLR: 1.25
Adolor says pain drugs failed in midstage trial
Adolor says 2 pain drug candidates didn't meet goal in study due to strong placebo response
Related Quotes
Symbol Price Change
ADLR 1.2600 -0.2400
Chart for Adolor Corporation
PFE 15.17 -0.30
Thursday June 17, 2010, 5:26 pm EDT
EXTON, Pa. (AP) -- Adolor Corp. said Thursday two experimental drugs failed in a clinical trial that tested them as treatments for pain caused by osteoarthritis of the knee.
Adolor said patients who were treated with a placebo experienced a surprisingly strong reduction in pain. As a result, neither of its drug candidates were significantly better than the placebo. There was also not a significant difference between the placebo and OxyContin in the study.
The company has one drug on the market: Entereg, a treatment for constipation following abdominal surgery. The two experimental drugs, dubbed ADL5859 and ADL5747, are its most advanced drug candidates. In aftermarket trading, Adolor stock dropped 20 cents, or 13.3 percent, to $1.30.
In the study, about 400 patients were treated twice a day with either 150 milligrams of ADL5859, 150 milligrams of ADL5747, 20 milligrams of OxyContin or placebo. The study compared the Adolor drugs with placebo to measure their ability to treat pain. The results were based on a survey given during the second week of treatment.
Adolor said the placebo response was surprising, but not unusual in studies of osteoarthritis treatments. Adolor and its partner Pfizer Inc. will review the data and decide whether they will continue testing the drugs as treatments for chronic inflammatory pain.
Adolor is running a separate study of ADL547 as a treatment for pain following a shingles infection, or postherpetic neuralgia. Data from that study is expected in the first quarter of 2011. |
